Literature DB >> 12642468

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

Ajay Madan1, Richard A Graham, Kathleen M Carroll, Daniel R Mudra, L Alayne Burton, Linda A Krueger, April D Downey, Maciej Czerwinski, Jameson Forster, Maria D Ribadeneira, Liang-Shang Gan, Edward L LeCluyse, Karl Zech, Philmore Robertson, Patrick Koch, Lida Antonian, Greg Wagner, Li Yu, Andrew Parkinson.   

Abstract

Cultured human hepatocytes are a valuable in vitro system for evaluating new molecular entities as inducers of cytochrome P450 (P450) enzymes. The present study summarizes data obtained from 62 preparations of cultured human hepatocytes that were treated with vehicles (saline or dimethylsulfoxide, 0.1%), beta-naphthoflavone (33 microM), phenobarbital (100 or 250 microM), isoniazid (100 microM) and/or rifampin (20 or 50 microM), and examined for the expression of P450 enzymes based on microsomal activity toward marker substrates, or in the case of CYP2C8, the level of immunoreactive protein. The results show that CYP1A2 activity was markedly induced by beta-naphthoflavone (on average 13-fold, n = 28 preparations), and weakly induced by phenobarbital (1.9-fold, n = 25) and rifampin (2.3-fold, n = 22); CYP2A6 activity tended to be increased with phenobarbital (n = 7) and rifampin (n = 3) treatments, but the effects were not statistically significant; CYP2B6 was induced by phenobarbital (6.5-fold, n = 13) and rifampin (13-fold, n = 14); CYP2C8 was induced by phenobarbital (4.0-fold, n = 4) and rifampin (5.2-fold, n = 4); CYP2C9 was induced by phenobarbital (1.8-fold, n = 14) and rifampin (3.5-fold, n = 10); CYP2C19 was markedly induced by rifampin (37-fold, n = 10), but relatively modestly by phenobarbital (7-fold, n = 9); CYP2D6 was not significantly induced by phenobarbital (n = 5) or rifampin (n = 5); CYP2E1 was induced by phenobarbital (1.7-fold, n = 5), rifampin (2.2-fold, n = 5), and isoniazid (2.3-fold, n = 5); and, CYP3A4 was induced by phenobarbital (3.3-fold, n = 42) and rifampin (10-fold, n = 61), but not by beta-naphthoflavone. Based on these observations, we generalize that beta-naphthoflavone induces CYP1A2 and isoniazid induces CYP2E1, whereas rifampin and, to a lesser extent phenobarbital, tend to significantly and consistently induce enzymes of the CYP2A, CYP2B, CYP2C, CYP2E, and CYP3A subfamilies but not the 2D subfamily.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642468     DOI: 10.1124/dmd.31.4.421

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  64 in total

1.  Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.

Authors:  Janne T Backman; Marika T Granfors; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

2.  Effect of rifampicin on the pharmacokinetics of pioglitazone.

Authors:  Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

3.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

Authors:  Yifan Zhang; Dayong Si; Xiaoyan Chen; Nan Lin; Yingjie Guo; Hui Zhou; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

4.  Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.

Authors:  Kajsa P Persson; Susanne Ekehed; Charlotta Otter; E S Mareike Lutz; Jane McPheat; Collen M Masimirembwa; Tommy B Andersson
Journal:  Pharm Res       Date:  2006-11-22       Impact factor: 4.200

5.  Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Authors:  Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pam Sheffels; Bojan Lalovic
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  HNF-4α determines hepatic differentiation of human mesenchymal stem cells from bone marrow.

Authors:  Mong-Liang Chen; Kuan-Der Lee; Huei-Chun Huang; Yue-Lin Tsai; Yi-Chieh Wu; Tzer-Min Kuo; Cheng-Po Hu; Chungming Chang
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

7.  Development and evaluation of an in vivo assay in Caenorhabditis elegans for screening of compounds for their effect on cytochrome P450 expression.

Authors:  Baby P S Chakrapani; Sandeep Kumar; Jamuna R Subramaniam
Journal:  J Biosci       Date:  2008-06       Impact factor: 1.826

8.  Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies.

Authors:  Martha Garcia; Joseph Rager; Qing Wang; Robert Strab; Ismael J Hidalgo; Albert Owen; Jibin Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

9.  Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes.

Authors:  Ritu Rana; Yuping Chen; Stephen S Ferguson; Grace E Kissling; Sailesh Surapureddi; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2010-01-19       Impact factor: 3.922

Review 10.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.